Paul G. Allen Frontiers Group [to 18 May 2019]
No new digest content identified.

BMGF – Gates Foundation [to 18 May 2019]
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 18 May 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 18 May 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
CARB-X funds Debiopharm to develop a new class of antibiotics to treat hospital-acquired pneumonia caused by multidrug-resistant superbug Acinetobacter baumannii
CARB-X is awarding Debiopharm International SA of Lausanne, Switzerland, up to $2.1 million in non-dilutive funding with the possibility of $1.6 million more if certain project milestones are met, to advance the development of a new class of antibiotics that inhibit bacterial fatty acid biosynthesis, an essential pathway in many drug-resistant bacterial species. This new class of antibiotics is in development for the treatment of hospital-acquired pneumonia caused by the multidrug-resistant superbug Acinetobacter baumannii.

CEPI – Coalition for Epidemic Preparedness Innovations [to 18 May 2019]
13 May 2019
ProMED Disease Outbreak Update
Update on Ebola outbreak in DRC, Rift Valley fever in Mayotte, and MERS outbreak in Saudi Arabia.

Clinton Health Access Initiative, Inc. (CHAI) [to 18 May 2019]
No new digest content identified.

EDCTP [to 18 May 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center [to 18 May 2019]
No new digest content identified.

European Medicines Agency [to 18 May 2019]
News and press releases
No new digest content identified.

European Vaccine Initiative [to 18 May 2019]
No new digest content identified.

FDA [to 18 May 2019]
No new digest content identified.

Fondation Merieux [to 18 May 2019]
No new digest content identified.

Gavi [to 18 May 2019]
17 May 2019
Gavi welcomes G7 initiative on primary health care
G7 health ministers adopt new primary health care initiative and call for strengthened health care at every stage of life

GHIT Fund [to 18 May 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.

Global Fund [to 18 May 2019]
Global Fund Board Steps Up the Fight Against AIDS, TB and Malaria
16 May 2019
[See Milestones above for detail]

Hilleman Laboratories [to 18 May 2019]
No new digest content identified.

Human Vaccines Project [to 18 May 2019]
No new digest content identified.

IAVI [to 18 May 2019]
May 16, 2019
IAVI and Liverpool School of Tropical Medicine to Partner in Snakebite Consortium
NEW YORK — May 16, 2019 — The International AIDS Vaccine Initiative (IAVI) and the Liverpool School of Tropical Medicine (LSTM) today announced a new global research consortium, the Scientific Research Partnership for Neglected Tropical Snakebite (SRPNTS). Funded with £9 million of UK aid from the UK government through the Department for International Development (DFID), this consortium will discover and develop novel monoclonal antibody (mAb) therapies to significantly improve the efficacy, safety, and affordability of snakebite treatment in India and Africa.
Joining IAVI and LSTM in the consortium are the Nigeria Snakebite Research & Intervention Centre (Bayero University, Kano), the Kenya Snakebite Research & Intervention Centre (Institute of Primate Research, Nairobi), the Indian Institute of Science (Bangalore), and Scripps Research (La Jolla). IAVI will coordinate the snakebite research partnership with funding provided by DFID over three years. The consortium will employ IAVI technologies and capabilities used originally for discovering HIV-specific broadly neutralizing antibodies (bNAbs) to develop new antivenom therapies.
“IAVI and its partners have over a decade of experience in researching broadly neutralizing antibodies against HIV to inform development of biomedical tools for HIV prevention, and we are committed to applying this expertise to help advance treatment and prevention for other diseases,” said IAVI President and CEO Mark Feinberg, M.D., Ph.D. “This partnership enabled by DFID allows us to work with LSTM and other experts to apply our antibody expertise to advance next-generation snakebite therapies for the world’s most vulnerable people.”…


No new digest content identified.

IFRC [to 18 May 2019]
Selected Press Releases, Announcements
Americas, Argentina
Major humanitarian conference to explore regional crises, migration
Buenos Aires/Panama/Geneva, 17 May 2018 – Red Cross leaders from across the Americas and around the world are gathering in Buenos Aires from 21-23 May for the 21st Inter-American Conference of the International Federation of Red Cross and Red Crescent …
17 May 2019

Africa, Democratic Republic of the Congo
DR Congo: We cannot scale down while Ebola escalates, says IFRC
Geneva, 16 May 2019 – The international community must urgently increase its investment in Ebola response efforts in the Democratic Republic of the Congo before the outbreak escalates further, warns the International Federation of Red Cross and Red Cre …
16 May 2019

Asia Pacific, DPRK
DPR Korea: Hunger warning after early drought
Early seasonal drought in the Democratic People’s Republic of Korea (DPRK) could exacerbate hunger, malnutrition and health problems for thousands of children, pregnant and breastfeeding women, older people and the chronically ill.

IVAC [to 18 May 2019]
No new digest content identified.

IVI [to 18 May 2019]
IVI News & Announcements
Former KSC Vice President Ms. Joanne Lee donates 50 million KRW to IVI
Ms. Joanne Lee, former Vice President of the Korea Support Committee for IVI and former Chairperson of the IVI Fundraising Campaign Committee (2005-2006), donated 50 million KRW (US$42,000) via KSC to support IVI’s vaccine research and development…

JEE Alliance [to 18 May 2019]
Selected News and Events
No new digest content identified.

MSF/Médecins Sans Frontières [to 18 May 2019]
Selected News; Project Updates, Reports [as presented on website]
Breaking the cycle: Paediatric DR-TB detection, care and treat…
Report 17 May 2019

“I have not seen such high numbers of measles cases”
Project Update 17 May 2019

Women and children continue to suffer in northeast Syria’s Al Hol …
Press Release 16 May 2019

Gaza, one year after the protests’ bloodiest day
Project Update 14 May 2019

Rohingya refugee crisis
Crisis Update 14 May 2019

Rohingya refugee crisis
Saving lives that have just begun in Cox’s Bazar
Project Update 13 May 2019

Update on MSF emergency response to Cyclones Idai and Kenneth
Crisis Update 13 May 2019

NIH [to 18 May 2019]
May 17, 2019
HIV Vaccine Awareness Day 2019 — May 18, 2019
— Statement by Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases, and Maureen M. Goodenow, Ph.D., NIH Associate Director for AIDS Research and Director, Office of AIDS Research
…We have the tools at hand that could — if fully implemented — end the HIV pandemic. Large clinical studies have proven that individuals with HIV who use antiretroviral therapy to achieve and maintain an undetectable viral load do not sexually transmit HIV to others—a concept known as undetectable = untransmittable (U=U). People who are at high risk for HIV can take a single daily pill known as PrEP, or pre-exposure prophylaxis, that is highly effective at protecting them from the virus. In addition, post-exposure prophylaxis, or PEP, provides a highly effective emergency means of preventing HIV transmission from a recent high-risk exposure and can serve as a bridge to PrEP….

Human antibody reveals hidden vulnerability in influenza virus
May 16, 2019 — Discovery by NIAID-funded researchers could aid quest for universal flu vaccine.

PATH [to 18 May 2019]
No new digest content identified.

Sabin Vaccine Institute [to 18 May 2019]
No new digest content identified.

UNAIDS [to 18 May 2019]
Selected Press Releases/Reports/Statements
17 May 2019
UNAIDS partners with Pride House Tokyo ahead of 2020 Olympic Games

16 May 2019
Declaration of the Rights of People Affected by Tuberculosis launched
Tuberculosis (TB) is the world’s number one cause of death from an infectious disease and remains the leading cause of death among people living with HIV, despite being preventable and curable. Reacting to the unacceptable burden of disease and death caused by TB, a new network of TB survivors and affected communities, called TB People, compiled the Declaration of the Rights of People Affected by Tuberculosis, with the support of leading human rights lawyers and the Stop TB Partnership.
The declaration, launched on 14 May at the Global Health Campus in Geneva, Switzerland, will guide countries to implement the commitments made at the 2018 United Nations High-Level Meeting on Tuberculosis and will inform the last board meeting of the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) before its replenishment meeting in Lyon, France, in October…

13 May 2019
HIV infections among children falling
The continuing fall in the number of children becoming infected with HIV is a major public health triumph. Globally, 1.6 million new child infections were averted between 2008 and 2017, an achievement that stems from a steep increase in the percentage of pregnant women living with HIV who receive antiretroviral medicines to prevent mother-to-child transmission of HIV or as lifelong therapy, from 25% in 2008 to 80% in 2017.
However, much remains to be done. Efforts to prevent mother-to-child transmission have been slowed by inconsistent treatment adherence among expectant and breastfeeding mothers living with HIV and by the significant numbers of pregnant and breastfeeding women with undiagnosed HIV. A high risk of HIV acquisition faced by women in Africa during pregnancy and breastfeeding has also been underappreciated.

UNICEF [to 18 May 2019]
Selected Statements, Press Releases, Reports
Press release
UNICEF and partners vaccinate hundreds of thousands of children affected by Cyclone Idai; stepping up life-saving cholera prevention work in northern areas affected by Cyclone Kenneth
APUTO, 16 May 2019 –  Hundreds of thousands of children affected by deadly Cyclone Idai in Mozambique have been vaccinated and received vitamin A supplements in the past week, with UNICEF and partners including the World Health Organisation (WHO) supporting the Government-led Health Week in the 21 most affected districts of Sofala, Manica, Inhambane, and Zambézia provinces.

To date more than 700,000 children have been vaccinated against Polio and more than 650,000 children against Measles and Rubella. Teams also reached nearly 700,000 children with vitamin A supplements; dewormed more than 550,000 children; more than 650,000 adolescent girls received Iron and folic acid supplements; and nearly 700,000 children were screened for malnutrition and acute case referred for life-saving treatment.  UNICEF appreciates the remarkable effort of health teams to overcome all barriers to reach every community with a broad, integrated package of services to promote the health and nutrition of children and pregnant women…

…To prevent the spread of cholera, UNICEF with partners in the Government-led Cholera Taskforce is operating Rapid Response teams which immediately deploy to households with reported cases, disinfecting houses and intensifying water treatment in neighboring homes.
In Pemba today, the Government-led Cholera Taskforce launched the cholera vaccination campaign, with support from UNICEF and partners. On 12 May, UNICEF flew in in Oral Cholera Vaccines to reach more than 250,000 people in Cyclone Kenneth-affected areas, purchased with the financial support of the Global Alliance for Vaccines and Immunization (GAVI). UNICEF-supported teams are conducting community awareness and outreach programmes, including working closely with religious and community leaders. Given the Ramadan period, additional measures are being put in place to be able to administer the Oral Cholera Vaccine respecting community needs.

“Cholera and other infectious diseases continue to be a major threat to children and families in these early days after Cyclone Kenneth,” said Mr Le Pechoux. “The two-round Oral Cholera Vaccine campaign is another key step in stopping the spread of cholera, at the same time as we keep our focus on safe water, sanitation and hygiene,” he said. “We are still in the critical days of emergency response to reach every family affected by Cyclone Kenneth, and we have a long way to go to ensure that every child is safe and healthy.”

Press release
1 in 7 babies worldwide born with a low birthweight – The Lancet Global Health, UNICEF, WHO
Progress is also slow in high-income countries including the UK, Finland, France, Germany, USA, Australia, and New Zealand.

Press release
UNICEF Executive Director Henrietta Fore addresses the UN Security Council on Yemen in New York, 15 May 2019
… Every 10 minutes, another child will die from a preventable cause.
Like a lack of food, with 360,000 children suffering from severe acute malnutrition. In fact, half the children under five years old in Yemen — 2.5 million — are stunted. And stunting is irreversible.
Like a lack of a simple vaccination — with 151 children dying of diphtheria since last August. Or like cholera and severe acute watery diarrhea. Despite the best efforts of the humanitarian community — including over two million doses of oral cholera vaccines delivered over the last year — there are over 135,000 suspected cases reported so far this year among children. Over 3,300 people have died of cholera since 2017 — including 153 children since January alone. A number that will increase as we head into the rainy season. And as always, the children die first…

Vaccine Confidence Project [to 18 May 2019]
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 18 May 2019]
No new digest content identified.

Wellcome Trust [to 18 May 2019]
No new digest content identified.

The Wistar Institute [to 18 May 2019]
Press Release
May. 15, 2019
Enhanced Anticancer Compound May Allow for Precise Activation and Tracking of Treatment
The compound requires activation with precise stimuli that would also cause emission of fluorescence for spatiotemporal control of activity.

World Organisation for Animal Health (OIE) [to 18 May 2019]
No new digest content identified.



BIO [to 18 May 2019]
May 17 2019
BIO Applauds Senate Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act
Washington, DC – The Biotechnology Innovation Organization (BIO) today applauds the Senate passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act (S. 1379). The legislation would re-authorize critical federal biodefense programs and agencies, including the BioShield Special Reserve Fund (SRF), the Biomedical Advanced Research and Development Authority (BARDA), and the Strategic National Stockpile (SNS). The legislation also authorizes funding for pandemic influenza product development and procurement for the first time…

DCVMN – Developing Country Vaccine Manufacturers Network [to 18 May 2019]
27 May 2019 to 30 May 2019
Advanced workshop: Vaccine Safety Monitoring and Pharmacovigilance
Sao Paulo – Brasil

IFPMA [to 18 May 2019]
No new digest content identified.

PhRMA [to 18 May 2019]
No new digest content identified.